# **Special Issue**

# Molecular Insights into Blood Coagulation and Inflammation

# Message from the Guest Editors

During the COVID-19 pandemic, the importance of the interference between inflammatory and haemostatic processes has received special attention due to the frequent findings of microthrombi in the lungs and other organs. This Special Issue focuses on defining the molecular mechanisms regulating thromboinflammation and its clinical importance in specific disease states. The aims of this Issue are: 1) To publish manuscripts focused on the pathogenesis of thromboinflammation in specific disease states; 2) To obtain insights into the parallels and differences between different thrombo-inflammatory disorders (sepsis, major trauma or severe COVID-19 infection): 3) To review the epidemiology as well as the laboratory and prognostic markers of severe thrombo-inflammation: 4) To analyse the data related to anticoagulation and immunomodulatory interventions and present novel therapeutic agents. Dr. Aniko Smudla

#### **Guest Editors**

Dr. Krisztián Tánczos

Dr. Anikó Sumdla

Dr. János Fazakas

## Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/157767

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).